ValiRx Plc Company Profile (LON:VAL)

Analyst Ratings

Consensus Ratings for ValiRx Plc (LON:VAL) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for ValiRx Plc (LON:VAL)
Show:
DateFirmActionRatingPrice TargetActions
7/29/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Northland SecuritiesReiterated RatingCorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Northland Capital PartnersReiterated RatingcorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/14/2014Daniel Stewart & CoReiterated RatingBuyGBX 1.05View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for ValiRx Plc (LON:VAL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ValiRx Plc (LON:VAL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ValiRx Plc (LON:VAL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ValiRx Plc (LON:VAL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ValiRx Plc (LON:VAL)
DateHeadline
07/28/16 07:33 PMValiRx PLC receives notification of patent grant allowance in New ... - Proactive Investors UK
07/28/16 10:28 AMValiRx receives notification of patent grant allowance in New Zealand for VAL401
07/28/16 02:28 AMNotification of New Zealand Patent Grant Allowance - [at noodls] - ValiRx Plc ('ValiRx' or 'the Company') ValiSeek Extends its International Patent Coverage for VAL401 London, UK., 28 July 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical ...
07/27/16 10:14 AMRisers & fallers: Baron Oil, Blenheim Natural Resources, Bluebird Merchant Ventures, Brave Bison, Harvest Minerals ... - Proactive Investors USA & Canada
07/26/16 10:39 AMRisers & fallers: Capital & Counties, China New Energy, Charles Taylor, Lamprell, Sunrise Resources, Taptica - Proactive Investors UK
07/26/16 10:39 AMRisers & fallers: Victoria, Management Resources Solutions, OptiBiotix Health, Orogen Gold, Clear Leisure, Man Group - Proactive Investors UK
07/26/16 10:39 AMRisers & fallers: Baron Oil, Blenheim Natural Resources, Bluebird Merchant Ventures, Brave Bison, Harvest Minerals ... - Proactive Investors UK
07/26/16 10:39 AMValiRx terminates convertible loan facility with Bracknor - Proactive Investors UK
07/26/16 01:28 AMIssue of Equity and Bracknor Facility Update - [at noodls] - ValiRx Plc ('ValiRx' or 'the Company' or 'the Group') Issue of Equity and Discontinuation of Bracknor Facility ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics ...
07/20/16 08:08 PMWere Analysts Bearish ValiRx Plc (LON:VAL) This Week? - Consumer Eagle
07/15/16 06:04 PMEthics Committee approval for ValiRx's Georgia site "very important"
07/15/16 12:23 PMEthics Committee approval for ValiRx's Georgia site "very important" - Proactive Investors UK
07/15/16 12:23 PMNorthland Capital Partners View on the City - ValiRx plc - Proactive Investors UK
07/14/16 10:44 AMValiRx : Receives Approval To Submit Application For Cancer Drug Trial
07/07/16 09:47 AMValiRx : Sale of TRAC Technology Rights for EUR 0.8 million
07/07/16 09:47 AMValiRx's sale of Finnish subsidiary will free up resources
07/07/16 01:21 AMSale of TRAC Technology Rights for EUR 0.8 million - [at noodls] - ValiRx Plc ('ValiRx' or 'the Company' or 'the Group') 'Sale of use of rights for TRAC Technology for €0.8 million' 'ValiRx to retain royalty-free rights to the technologies for the company's therapeutic ...
07/06/16 06:31 AMValiRx Plc Has Another Very Strong Trading Session - Engelwood Daily
07/02/16 09:40 AMEpigenetics Market Is Expected To Gain From Enhanced Need Of Rapid And Accurate Detection Techniques Till 2022 ... - Press Release Rocket
06/27/16 06:31 AMValiRx : Notice of GM
06/24/16 09:41 AMTesco turnaround a “leap of faith” for investors, says analyst - Proactive Investors UK
06/24/16 09:41 AMSummit Therapeutics "can alter treatment paradigm" for CDI - Proactive Investors USA & Canada
06/23/16 07:52 PMTelco Systems chief seeing high demand; working on tier-1 deals - Proactive Investors UK
06/23/16 09:36 AMMetal Tiger produces “astonishingly high grade figures”, says CEO - Proactive Investors UK
06/23/16 09:36 AMGreatland Gold is in a proactive phase of exploration, say directors - Proactive Investors UK
06/08/16 10:14 AMValiRx in talks over cancer drug collaborations, says chief
06/07/16 09:58 AMValiRx starts preparations for efficacy trial of cancer drug
05/26/16 10:40 AMValiRx : Posting of Annual Report & Notice of AGM - London, UK, 26 May 2016: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine. The Company announces that its Annual Report and Accounts for the year ended 31 December 2015 has been ...
05/19/16 11:18 AMValiRx updates market on 'significant' 2015 -
05/18/16 11:12 AMConversion of Loan Note, issue of warrant & equity - [at noodls] - ValiRx Plc ('ValiRx' or the 'Company') Drawdown of £500,000 of Convertible Loan Notes and issue of warrants Issue of Convertible Loan Note ('CLN') ValiRx Plc (AIM: VAL), a life science company with a focus ...
04/29/16 01:27 AMNotification of US Patent Grant for VAL401 - [at noodls] - 29 April 2016 ValiRx Plc ('ValiRx' or 'the Company') ValiSeek Update '' ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased ...
04/22/16 04:21 AMValiRx to exhibit at the UK Investor Show - [at noodls] - ValiRx Plc ('ValiRx' or 'the Company') COMMUNICATIONS UPDATE '' London, UK, 22 April 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised ...
03/31/16 01:36 AMValiRx to exhibit and present at the AACR - [at noodls] - ValiRx Plc ('ValiRx' or 'the Company') ValiRx is exhibiting and presenting at the prestigious AACR London, UK, 31st March 2016: ValiRx Plc(AIM: VAL), a life science company with a focus on cancer diagnostics ...
03/21/16 02:18 AMConvertible Loan Facility of up to £4.0 million - [at noodls] - ValiRx Plc ('ValiRx' or the 'Company') and Issue of Warrants to enable expansion of the VAL201 trial to a multi-centre study London, UK. 21 March 2016: ValiRx Plc (AIM: VAL), a life science company with ...
02/26/16 11:35 AMWhat Do Analysts Think Of Valirx (LON:VAL) This Week? - Risers & Fallers - What Do Analysts Think Of Valirx (LON:VAL) This Week?Risers & FallersValirx (LON:VAL) has decreased by -52.73% over 12 months. ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and ...
02/26/16 11:35 AMWhat's in ValiRx Plc After Today's Huge Decline? - Franklin Independent - What's in ValiRx Plc After Today's Huge Decline?Franklin IndependentThe stock of ValiRx Plc (LON:VAL) is a huge mover today! The stock decreased 6.83% or GBX 0.97 on February 24, hitting GBX 13.28. About 310,889 shares traded hands. ValiRx Plc (LON:VAL) has declined 67.50% since July 24, 2015 and is downtrending.and more »
02/16/16 07:33 AMValiRx achieves success in latest VAL201 trial -
02/14/16 01:08 PMWhat Next for ValiRx Plc Stock After Today's Huge Decline? - Sonoran Weekly Review - What Next for ValiRx Plc Stock After Today's Huge Decline?Sonoran Weekly ReviewThe stock of ValiRx Plc (LON:VAL) is a huge mover today! The stock is down 0.06% or GBX 0.01 after the news, hitting GBX 17.49 per share. About 445,475 shares traded hands or 107.21% up from the average. ValiRx Plc (LON:VAL) has declined 48.53% ...and more »
02/09/16 01:48 PMRockhopper Exploration to present at the SHARES Investor Evening in Edinburgh on 25th February 2016 - Stock Market Wire - Rockhopper Exploration to present at the SHARES Investor Evening in Edinburgh on 25th February 2016Stock Market WireStockMarketWire.com - Stewart MacDonald, CFO of Rockhopper Exploration (RKH) (LSE:RKH) will be giving a briefing at the SHARES Investor Evening on 25th February 2016. It will take place in Edinburgh at an investor evening being organised by Shares ...and more »
02/09/16 01:48 PMInstem to present at the SHARES Investor Evening in Edinburgh on 25th February 2016 - Stock Market Wire - Instem to present at the SHARES Investor Evening in Edinburgh on 25th February 2016Stock Market WireStockMarketWire.com - Phil Reason, CEO of Instem Plc (INS) (LSE:INS) will be giving a briefing at the SHARES Investor Evening on 25th February 2016. It will take place in Edinburgh at an investor evening being organised by Shares Magazine; the event is ...and more »
02/09/16 01:48 PMValiRx Shares Rise After Positive Clinical Trial News For VAL201 - London South East (registration) (blog) - ValiRx Shares Rise After Positive Clinical Trial News For VAL201London South East (registration) (blog)LONDON (Alliance News) - ValiRx PLC on Tuesday said its Phase l/ll clinical trial of VAL201 has shown a high degree of safety. The life science company, which focuses on cancer diagnostics and therapeutics for personalised medicine, said the compound ...and more »
02/09/16 01:48 PMValiRx : Quarterly Update on Clinical Progress - This estimate is widely considered to be an under estimation of the true situation with respect to this condition. About ValiRx Plc ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics.
02/09/16 01:48 PMQuarterly Update on Clinical Progress - London, UK, 9 th February 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, provides a quarterly update on clinical progress. Following on from the Company's update on 19 ...
02/09/16 01:48 PMValiRx Shares Rise After Positive Clinical Trial News For VAL201 - LONDON (Alliance News) - ValiRx PLC on Tuesday said its Phase l/ll clinical trial of VAL201 has shown a high degree of safety. The life science company, which focuses on cancer diagnostics and therapeutics for personalised medicine, said the compound is ...
02/09/16 09:01 AMValiRx confident in two ongoing clinical trials -
02/04/16 01:18 PMEpigenetics Market Is Expected To Reach $16.31 Billion By 2022: New Report By Grand View Research, Inc. - GlobeNewswire (press release) - Epigenetics Market Is Expected To Reach $16.31 Billion By 2022: New Report By Grand View Research, Inc.GlobeNewswire (press release)Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation. Extensive R&D initiatives aimed at the development of novel drugs and the presence of strong product pipeline is expected to ...and more »
02/04/16 01:18 PMEpigenetics Market Is Expected To Reach $16.31 Billion By 2022: New Report By Grand View Research, Inc. - Inc., Valirx Plc and Sigma-Aldrich Corporation. Extensive R&D initiatives aimed at the development of novel drugs and the presence of strong product pipeline is expected to further boost market growth over the forecast period. Request for free sample of ...
01/30/16 07:17 PMAnalysts Consensus For Valirx (LON:VAL) - Risers & Fallers - Analysts Consensus For Valirx (LON:VAL)Risers & FallersValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and ...
01/28/16 12:41 PMAngle expects "deluge of news" in months ahead as Parsortix makes progress - Proactive Investors UK - Angle expects "deluge of news" in months ahead as Parsortix makes progressProactive Investors UKAndrew Newland, chief executive officer at Angle PLC (LON:AGL), tells Proactive Investors the latest interim release marks six months of "consistent progress" against the company's strategy. He says he hopes Angle will be the first company authorised ...and more »
01/26/16 12:46 PMBeaufort Securities Breakfast Alert including Motif Bio and SerVision - Proactive Investors UK - Beaufort Securities Breakfast Alert including Motif Bio and SerVisionProactive Investors UKYesterday, Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing ...and more »

Social

About ValiRx Plc

ValiRx Plc logoValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. Its NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through three divisional companies: ValiPharma, ValiFinn and ValiSeek.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: VAL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.09
  • 50 Day Moving Average: $7.87
  • 200 Day Moving Average: $11.31
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $3.06M
  • Current Year EPS Consensus Estimate: $0.00 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: